SG293
/ Sana Biotech
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
November 06, 2025
Sana intends to explore SG293 in both B-cell cancers and B-cell mediated autoimmune diseases. The company expects to file an IND for SG293 as early as 2027.
(GlobeNewswire)
IND • Immunology • Oncology
1 to 1
Of
1
Go to page
1